Utilização das células-tronco mesenquimais na terapia para o Covid-19
Carregando...
Data
2021-12-16
Tipo de documento
Monografia
Título da Revista
ISSN da Revista
Título de Volume
Área do conhecimento
Ciências da Saúde
Modalidade de acesso
Acesso aberto
Editora
Autores
Mendonça, Eduarda Cristina Pereira
Franco, Débora de Siqueira
Orientador
Loyola, Ana Beatriz Alkmim Teixeira
Coorientador
Sá, André Luís Braghini
Resumo
No final de 2019 surgiu na China uma doença causadora de pneumonia grave
que teve identificado como agente etiológico o vírus SARS-CoV-2, sendo
denominado como Covid-19 e em março de 2020 foi declarada a pandemia pela
Organização Mundial de Saúde. O Covid-19 é uma doença potencialmente
grave, que apresenta alta mortalidade por causar a doença respiratória aguda e
grave. Acredita-se que essa doença respiratória apresente um agravamento
devido à hiperinflamação causada pelo sistema imunológico ao tentar combater
o vírus, denominando-se cascata de citocinas. Nesse sentido, surgem as
Células-tronco mesenquimais (CTM)¸ que atualmente já são estudadas e
utilizadas para combater a cascata de citocinas em situações como a Doença do
Enxerto contra o Hospedeiro (DECH). Com isso, o presente trabalho é uma
revisão sistemática da literatura científica que tem objetivo de pesquisar os
estudos clínicos que utilizaram as CTM no combate à Covid-19. Para isso se
utilizou as plataformas de busca PubMed e Scielo com o cruzamento de
palavras-chave. Foram encontrados 11 artigos que utilizaram CTM para o
tratamento de Covid-19. Esses ensaios clínicos utilizaram CTM de diferentes
fontes do organismo, como sangue de cordão umbilical, placenta, Geleia de
Wharton e sangue menstrual. Todos os ensaios clínicos mostraram-se seguros,
não demonstrando reações adversas graves. Também foi demonstrada que são
eficazes para o tratamento da Covid19 grave.
At the end of 2019, a disease-causing severe pneumonia emerged in China, identified as the etiologic agent of the SARS-CoV-2 virus, being named Covid-19 and in March 2020 the World Health Organization declared a pandemic. Covid19 is a potentially serious disease, with high mortality due to acute and severe respiratory disease. It is believed that this respiratory disease has aggravation due to hyperinflammation caused by the immune system when trying to fight the virus, called cascade and cytokines. In this sense, Mesenchymal Stem Cells (MSCs)¸ appear, which are currently being studied and used to combat the cytokine storm in situations such as Graft versus Host Disease (GVHD). Therefore, this article is a systematic review of the scientific literature that aims to research clinical studies that used MSCs to combat Covid-19. For this, the PubMed and Scielo search platforms were used with the crossing of keywords. Eleven articles were found that used CTM for the treatment of Covid-19. These clinical trials used MSCs from various sources in the body, such as umbilical cord blood, placenta, Wharton's Jelly, and menstrual blood. All clinical trials have been shown to be safe, not showing serious adverse reactions, they have also been shown to be effective for the treatment of severe Covid-19.
At the end of 2019, a disease-causing severe pneumonia emerged in China, identified as the etiologic agent of the SARS-CoV-2 virus, being named Covid-19 and in March 2020 the World Health Organization declared a pandemic. Covid19 is a potentially serious disease, with high mortality due to acute and severe respiratory disease. It is believed that this respiratory disease has aggravation due to hyperinflammation caused by the immune system when trying to fight the virus, called cascade and cytokines. In this sense, Mesenchymal Stem Cells (MSCs)¸ appear, which are currently being studied and used to combat the cytokine storm in situations such as Graft versus Host Disease (GVHD). Therefore, this article is a systematic review of the scientific literature that aims to research clinical studies that used MSCs to combat Covid-19. For this, the PubMed and Scielo search platforms were used with the crossing of keywords. Eleven articles were found that used CTM for the treatment of Covid-19. These clinical trials used MSCs from various sources in the body, such as umbilical cord blood, placenta, Wharton's Jelly, and menstrual blood. All clinical trials have been shown to be safe, not showing serious adverse reactions, they have also been shown to be effective for the treatment of severe Covid-19.
Palavras-chave
Células tronco Mesenquimais, Covid-19, Tratamento